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The traditional assumption is that human tumour
responses are relatively insensitive to fraction size
compared to dose-limiting late reacting normal tissues.
This assumption is consistent with the responses of animal
tumours and of human squamous carcinomas of the
cervix uteri, lung and head and neck [1-3]. The data show
that as fraction size increases above 2.0 Gy, the ratio of
tumours cured to late adverse effects falls, a highly
unfavourable relationship. This may not apply to all
tumour types, though. The fractionation sensitivity of
normal tissues and tumours is well described by a linear-
quadratic model [4]. The α/β value in this simple
empirical formula (units Gy) is a practical descriptor of
the sensitivity to fraction size. Values of α/β in the range
1-6 Gy are typical of late responding tissues, with higher
values (≥10 Gy) typical of squamous carcinomas and early
responding normal tissues. The hypothesis relevant to
the present discussion is that α/β values for breast cancer
are closer to those of late normal tissue responses than to
human squamous carcinoma. The implication of this
hypothesis is that hypofractionation should be evaluated
for the treatment of primary breast cancer (the following
arguments do not apply to treatment of the lymphatic
pathways due to the high fractionation sensitivity of the
brachial plexus).
An α/β value in the range 4-5 Gy was first estimated
for the response of locally advanced and recurrent chest
wall breast cancer in the early 1950’s, and analysed using
the linear quadratic model in the mid-1980’s [5, 6]. More
recently, a direct estimate of 4.1 Gy (95% CI 1.0–9.7)
was reported for the fractionation sensitivity of breast
cancer in the Royal Marsden Hospital/Gloucestershire
Oncology Centre Breast Fractionation Trial (N=1,410)
[7]. Meanwhile, a randomised comparison of 50 Gy in 25
fractions of 2.0 Gy and 42.5 Gy in 16 fractions of 2.67
Gy (N=1,234) in Ontario reported no significant differen-
ces in local tumour recurrence between arms [8]. If the
two Ontario schedules are truly iso-effective with respect
to tumour control, it implies an α/β value of 3 Gy (this
could be an underestimate if the difference between 5
weeks and 3 weeks treatment time is relevant). Similar
fractionation sensitivity, including an α/β value as low as
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negatively affected the ratio of curability to late adverse effects. However, there now exists data to suggest that hypofractionation
may be advisory in breast cancer. The author presents a number of recently published and currently ongoing trials, which may
provide evidence for the use of hypofractionated radiotherapy in breast cancer patients. The possible implications for primary
breast cancer are that modest increase in fraction size combined with reduction in treatment time may translate into
worthwhile gains in tumour control, without enhanced late normal tissue injuries. This may affect future decision-making in
the course of radiotherapy for breast cancer if the onging trials are confirmatory.
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1.5 Gy, has recently been suggested for prostate cancer
[9].
The UK Standardisation of Radiotherapy (START)
Trial is testing the fractionation sensitivity of breast cancer
in a design that incorporates two randomisations: Trial A
(N=2,236) is an explanatory trial that tests 50 Gy in 25
fractions of 2.0 Gy against two dose levels of a 13-fraction
regimen delivering 3.0 Gy or 3.2 Gy fractions over 5
weeks; Trial B (N=2,215) is a pragmatic trial testing
50 Gy in 25 fractions against 40 Gy in 15 fractions of 2.67
Gy. If the relatively high fractionation sensitivity of breast
cancer is confirmed (no results have been reported to
date), the implications are that larger fraction sizes have
no disadvantages, and perhaps significant advantages, for
women with primary breast cancer. Since it is unlikely
that 13- or 15-fraction schedules would represent the
limit of what might be achieved, further studies are
justified to test the limits of hypofractionation in breast
cancer.
For example, 5 fractions of 5.7 or 6.0 Gy are
predicted by the linear quadratic model to be equivalent
to 25 fractions of 2.0 Gy, assuming α/β values of 3.0 Gy or
4.0 Gy, respectively [4]. Based on human skin responses,
the linear-quadratic model performs reliably over this
range of radiation fraction sizes [10, 11]. However, there is
limited human experience with once-weekly fractionation
in the context of breast cancer radiotherapy. Six fractions
of 6.5 Gy over 6 weeks to the whole breast or chest wall
using tangential megavoltage fields were evaluated in a
series of 84 patients followed up for 36–94 months at
Guildford, UK [12]. Acute skin reactions were reportedly
mild and only 1/36 patients treated to whole breast
developed a severe delayed skin reaction. In a recent
French study, 152 women were treated with 5 fractions of
6.5 Gy over 5 weeks with 3 local relapses at a median
follow up of >5 years, but no comments on normal tissue
responses [13]. Randomised clinical trials are needed to
formally test the safety of this approach prior to
evaluating efficacy (tumour control) in a large trial. This
is the background to the ongoing UK FAST Trial
(N=900) that tests 50 Gy in 25 fractions of whole breast
radiotherapy against 2 dose levels of a 5-fraction schedule
delivered over 5 weeks (5.7 Gy or 6.0 Gy per fraction)
using 3D radiation dose compensation. The primary
endpoint is late normal tissue response. If the 3-year data
are encouraging, a large phase 3 trial will be needed to
evaluate local tumour control, quality of life and health
economic consequences.
Hypofractionation lends itself to acceleration, taking
advantage of the relative sparing of early skin reactions as
fraction size increases and the absence of a significant
time dependency for late adverse effects. Tumour
repopulation has recently been tested as a determinant of
treatment outcome in the context of adjuvant systemic
therapy. In a randomised comparison of conventional
3-weekly schedules of doxorubicin and cyclophosphamide
with the same chemotherapy doses given at 2-weekly
intervals (using growth factors to accelerate marrow
recovery), the hazard ratios for disease-free and overall
survival associated with 2-weekly chemotherapy were 0.74
(p=0.01) and 0.69 (p=0.01), respectively in 2,005 patients
[14]. Recent reports of accelerated radiotherapy
fractionation in head and neck cancer indicate that very
modest shortening of treatment has a detectable impact
on local control. In a trial of 1,476 patients randomised to
5 (control arm) or 6 (test arm) fractions per week of
conventional radiotherapy, local tumour control in the
test arm was 76% patients compared to 64% in the
control group [15]. In this study, shortening treatment
by only 7 days was associated with a 12% absolute
reduction in local recurrence at the primary site, a
reduction in the odds of recurrence of 16%. The possible
implications for primary breast cancer are that modest
reductions in treatment time may translate into
worthwhile gains in tumour control without enhanced
late normal tissue injuries. If the predicted late adverse
effects of once-weekly 5.7-6.0 Gy fraction sizes are
confirmed in the current FAST trial, it may justify future
evaluation of accelerated hypofractionated radiotherapy. 
Finally, the implications of advanced techniques
(intensity modulated radiotherapy) for delivering the
biological advantages of hypofractionation are worth
considering. Rather than increase dose intensity by
increasing the number of 2.0 Gy fractions, it creates
opportunities for escalating dose intensity by modulating
fraction size (this argument does not hold for the
lymphatic pathways). Even if the fractionation sensitivity
(as expressed by the α/β value) of breast cancer is not
quite as great as the normal tissues of the breast, shorter
overall treatment times needed to deliver concomitant
boost using intensity modulated radiotherapy could be
advantageous if tumour proliferation is a significant
determinant of local control. The implications of
dose escalated intensity modulated radiotherapy are
under test in the forthcoming UK IMPORT Trial. The
hypothesis is that higher doses per fraction to high-risk
areas and lower fraction sizes to low-risk areas of the
breast will offer a clinically superior and cost-effective
approach of matching dose intensity to tumour recurrence
risk compared to standard sequential boost techniques. In
conclusion, future prospects for exploiting the biology of
hypofractionation in breast cancer using advanced
radiotherapy technologies look bright, with prospects for
testing a 5-fraction, perhaps even a 5-day, schedule of
dose escalated intensity modulated radiotherapy by the
end of the decade.
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